0001193125-20-135013.txt : 20200506 0001193125-20-135013.hdr.sgml : 20200506 20200506170056 ACCESSION NUMBER: 0001193125-20-135013 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 EFFECTIVENESS DATE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GW PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001351288 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35892 FILM NUMBER: 20853442 BUSINESS ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 BUSINESS PHONE: 44 1223 266800 MAIL ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 DEFA14A 1 d849216ddefa14a.htm DEFA14A DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.        )

 

 

Filed by the Registrant  ☒                                Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

☐    Preliminary Proxy Statement
☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐    Definitive Proxy Statement
☒    Definitive Additional Materials
☐    Soliciting Material under §240.14a-12

GW PHARMACEUTICALS PLC

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒    No fee required.
☐    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
   (1)   

Title of each class of securities to which transaction applies:

 

     

   (2)   

Aggregate number of securities to which transaction applies:

 

     

   (3)   

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

   (4)   

Proposed maximum aggregate value of transaction:

 

     

   (5)   

Total fee paid:

 

     

☐

    Fee paid previously with preliminary materials.

☐

    Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
   (1)   

Amount Previously Paid:

 

     

   (2)   

Form, Schedule or Registration Statement No.:

 

     

   (3)   

Filing Party:

 

     

   (4)   

Date Filed:

 

     

 

 

 

SUPPLEMENT

TO

PROXY STATEMENT

FOR

ANNUAL GENERAL MEETING OF SHAREHOLDERS

to be held on May 26, 2020

The date of this Supplement is May 6, 2020.

On April 7, 2020, GW Pharmaceuticals plc (the “Company”) filed a definitive proxy statement (the “Proxy Statement”) relating to the Company’s 2020 Annual General Meeting of Shareholders (“AGM”). The Company has set May 26, 2020 as the date for the AGM. The meeting will be held at the Company’s office at Kingsgate House, Newbury Rd, Andover, SP10 4DU, England at 4:00 p.m. local time. As previously disclosed, the record date for determining the holders of the Company’s American Depositary Shares entitled to vote at the AGM has been fixed as the close of business on March 31, 2020. This Supplement supplements, amends and should be read in conjunction with the Proxy Statement in order to add information regarding director attendance at the meetings of the Company’s Board of Directors and the committees of the Board of Directors.

Board of Director Meetings and Committees Attendance

During the Company’s fiscal year ended December 31, 2019, each director attended at least 75% of the aggregate number of meetings of the Board of Directors and the committees of the Board of Directors on which he or she served.